Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/25/2018 |
| Start Date: | March 31, 2012 |
| End Date: | November 30, 2013 |
A Randomized, Open-label, Phase 2 Study Of Mdv3100 As A Neoadjuvant Therapy For Patients Undergoing Prostatectomy For Localized Prostate Cancer
The purpose of this study is to determine if enzalutamide is an effective therapy in treating
localized prostate cancer prior to prostatectomy.
localized prostate cancer prior to prostatectomy.
Inclusion Criteria:
- Willing to provide informed consent
- 18 years of age or older
- Histologically confirmed adenocarcinoma of the prostate
- Must be a candidate for radical prostatectomy and considered surgically resectable
Exclusion Criteria:
- Stage T4 prostate cancer by clinical or radiologic evaluation
- Treatment with an investigational agent within 4 weeks prior to randomization
- Received therapy for other neoplastic disorders within 5 years
- Hypogonadism or severe androgen deficiency
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials